 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Kezar Life Sciences, Inc. Nasdaq: KZR, a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted the broad therapeutic potential of KZR-616, a first-in-class immunoproteasome inhibitor, in two poster sessions during the American College of Rheumatology Annual Meeting ACR Convergence 2020. Both posters can be found on Kezars website under the Science 